The National Trial Lawyers
  • Home
    • Meet Our Team
    • Contact Us
    • Mission & Goals
    • FAQ
  • Webinars
  • News
  • Membership Directory
    • Top 100 Map – Civil Plaintiff
    • Top 100 Map – Criminal Defense
    • Top 40 Under 40 Map – Civil Plaintiff
    • Top 40 Under 40 Map – Criminal Defense
  • Top 100
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Benefits
    • About
    • Top 100 President’s Message
    • Diplomat
    • Membership Renewal
    • Member Profile Updates
    • Top 100 Badge
    • Media
  • Top 40
    • Civil Plaintiff Officers / Executive Committee
    • Criminal Defense Officers / Executive Committee
    • Top 40 Under 40 Trial Academy Bootcamp
    • Benefits
    • About
    • Top 40 President’s Message
    • Membership Renewal
    • Member Profile Updates
    • Top 40 Badge
    • Media
  • Specialty Assoc
    • About
    • Shop
    • Officers
    • Membership Renewal
    • Member Profile Updates
    • Media
  • Nominate
    • Top 100
    • Top 40
    • Specialty Association
    • Trial Lawyer Hall of Fame
    • Trial Lawyer of the Year
    • Trial Team of the Year
    • America’s Most Influential Trial Lawyer
    • America’s Most Influential Law Firm
    • Lifetime Achievement Award
  • Shop
  • Magazine
    • A-List
  • Education and Networking Agenda
    • Trial Lawyers Summit
      • Summit Sponsors
    • Top 40 Under 40 Trial Academy Boot Camp
    • Mass Torts Made Perfect
    • The Lanier Master Class 5.0 Trial Academy 2021
    • Webinars
  • Hall of Fame
    • Trial Lawyer Hall of Fame

Taxotere Chemotherapy Drug Maker Failed To Disclose Risk of Permanent Hair Loss

Posted on April 11, 2016 by Larry Bodine
taxotere hair loss

Sanofi-Aventis used misleading marketing to indicate that temporary hair loss could occur, but would grow back.

Cancer survivors around the country are filing lawsuits against drug manufacturer Sanofi-Aventis for its failure to warn about the risk of permanent hair loss with the use of its chemotherapy drug Taxotere.

The drug, commonly referred to as docetaxel, is a part of a family of drugs referred to as taxanes, which are used as chemotherapy agents that prevent cancer cells from growing and dividing.  Taxanes are used for the treatment of breast cancer, lung cancer, advanced stomach cancer, head and neck cancer, and metastatic prostate cancer.  There are several brands of taxanes that exist, including several generic forms.

The Taxotere lawsuits claim Sanofi-Aventis failed to warn patients and physicians of the increased risks of permanent hair loss, or permanent alopecia, even after treatment ends.  Sanofi-Aventis designed Taxotere to have an increased potency as compared to other taxanes, claiming that it was novel and merited for patent protection.  Because of its market exclusivity, Sanofi-Aventis was able to restrict competition and earn billions of dollars in revenues.

Marketed as superior to other chemo drugs

Also read: Indiana Employees with Cancer Sue Dry Cleaner for Poisoning Water

The manufacturer marketed Taxotere as superior to other treatments because of its increased potency.  The increased potency leads to an increased toxicity that is directly related to the increased adverse side effects, including permanent hair loss.

Although alopecia is a common side effect related to chemotherapy, Sanofi-Aventis used misleading marketing to indicate that temporary hair loss could occur, but would grow back.

One lawsuit alleges that Sanofi-Aventis knew of the increased risk of permanent hair loss because it disclosed the risks to patients and regulatory agencies in other countries, but failed to disclose the information in the United States.

Manufacturer aware of risk

Sanofi-Aventis further failed to disclose the results of additional studies it conducted that provided new facts about the risks associated with Taxotere use.

Research findings published by the National Cancer Research Institute found that 10-15 percent of patients who received Taxotere suffered from permanent hair loss.  Another study found that severe alopecia – an emotionally distressing side effect among female patients – was a reported complication of treatment with the drug.

The lawsuit states the Taxotere manufacturers “prayed on one of the most vulnerable group of individual’s at the most difficult time in their lives” and earned billions of dollars of revenues at the expense of “unwary cancer victims simply hoping to survive their condition and return to a normal life.”

Safer options available

The lawsuits state that if Sanofi-Aventis had properly warned patients and physicians of the increased risk of permanent alopecia by using Taxotere during chemotherapy, they would have been prescribed a different chemotherapy drug called Taxol, which is more effective than Taxotere, and does not result in permanent hair loss.

At this time, there has not been a recall of Taxotere, however the U.S. Food and Drug Administration acknowledged that Taxotere can result in permanent hair loss and required that the manufacturer place a warning on the label in December 2015.

Individual lawsuits have been filed, but there has not been any large group settlements involving Taxotere.  It is likely that the individual lawsuits will be combined in a multi-district litigation (MDL) case.

Grounds for filing a Taxotere permanent alopecia lawsuit include;

  • Failure to warn because Sanofi-Aventis failed to label its product or warn patients or physicians about the risks of permanent alopecia.
  • Fraudulent misrepresentation because Taxotere manufacturers falsely represented that it rigorously tested the drug and determined it was safe for its intended use.
  • Misleading marketing because Sanofi-Aventis was aware that Taxotere increased the risk of permanent alopecia, but made false and misleading statements that it was a superior drug as compared to other similar drugs, which do not cause permanent hair loss.
  • Concealed knowledge of hair loss risk because Sanofi-Aventis did not disclose the information they had on the drugs risk for permanent hair loss in the United States, although they included the warnings to patients and regulatory agencies in other countries.

 

Posted in Blog, Class Actions, Consumer Protection, Mass Torts, Medical Malpractice, Product Liability

Comments are closed.

News Categories

Subscribe to Blog and VFJ via Email

Enter your email address to subscribe to this blog, the Voice for Justice and receive notifications of new posts by email.

Read about other Top Jury Verdicts

Pharmaceutical Giant Johnson & Johnson is Preparing $3.9B for Talc Settlements

Pharmaceutical Giant Johnson & Johnson is Preparing $3.9B for Talc Settlements

Pharmaceutical giant Johnson & Johnson has set aside $3.9 billion for talc-related litigation, according to a regulatory [Read More...]
Alaska Airlines Will Pay $3.19M Following the Death of a Passenger

Alaska Airlines Will Pay $3.19M Following the Death of a Passenger

Seattle-based Alaska Airlines has been ordered to pay more than $3 million to the family of a passenger of reduced mobility w[Read More...]
No thumbnail available

Keith Givens on the Trial Lawyers Summit and Lanier Trial Academy

https://vimeo.com/515910581 Michelle Swanner, Executive Director of The National Trial Lawyers, interviews Keith Givens[Read More...]
A $220M Settlement Reached in National Milk Producers' Herd Retirement Program

A $220M Settlement Reached in National Milk Producers' Herd Retirement Program

ST. LOUIS, Feb. 22, 2021 /PRNewswire/ -- A $220 million settlement has been reached in a class-action law[Read More...]
Mountaire Farms Proposes a $65M Settlement for Contaminating the Millsboro-Area Groundwater and Air

Mountaire Farms Proposes a $65M Settlement for Contaminating the Millsboro-Area Groundwater and Air

It’s a lawsuit that’s been years in the making, but the class-action suit against Mountaire Farms may be approach[Read More...]

#LegalNews

@@TheNTLtop100

Contact Us | Terms of Use | Privacy Policy

Attorney information and content provided on this website is provided for the benefit of members of The National Trial Lawyers and as a public service by Legal Associations Management, Inc. The website and all data are the property of Legal Associations Management, Inc. Data, including without limitation attorney information and content, on the site may not be mined, sold, or used commercially for any purpose without the explicit written consent of Legal Associations Management, Inc. This site may not be accessed by any automated program for extracting data for any use. By accessing and using the site you agree that you will not develop, support or use software, devices, scripts, robots, or any other means or processes (including crawlers, browser plug-ins and add-ons, or any other technology) to scrape data or otherwise copy profiles and other data. Unauthorized use or attempted unauthorized use of this system may subject you to both civil and criminal penalties.